Haemonetics Corporation (HAE) key performance indicators and operating metrics (10 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings per Diluted Share | 1.29 USD_per_share | FY2026-Q4 |
| Adjusted Gross Margin | 59.70 percent | FY2026-Q4 |
| Adjusted Operating Margin | 24.40 percent | FY2026-Q4 |
| Blood Center Revenue Growth | 56.4M | FY2026-Q4 |
| Hospital Revenue Growth (Reported Basis) | 159.6M | FY2026-Q4 |
| Plasma Revenue Growth (Reported Basis) | 130.3M | FY2026-Q4 |
| Free Cash Flow | 44.5M | FY2026-Q4 |
| Organic Revenue Growth | 1.20 percent | FY2026-Q3 |
| Adjusted Operating Income | 89.2M | FY2026-Q3 |
| Organic Revenue Growth Excluding CSL | 9.40 percent | FY2026-Q2 |
Back to HAE overview · HAE earnings · HAE holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.